Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;68(4):821-827.
doi: 10.1136/jim-2020-001291. Epub 2020 Apr 1.

Clinical update on pulmonary hypertension

Salim Yaghi  1 , Anastasia Novikov  1 , Theo Trandafirescu  2
Affiliations
Review

Clinical update on pulmonary hypertension

Salim Yaghi et al. J Investig Med. 2020 Apr.

Abstract

Pulmonary hypertension (PH) is a chronic, complex and challenging disease. Advances in treatment are for the subset of patients with pulmonary arterial hypertension. Selected review of the literature was conducted incorporating the European Society of Cardiology/European Respiratory Society 2015 guidelines and recommendations from the Sixth World Symposium on Pulmonary Hypertension. PH is classified into five groups based on WHO classification. Echocardiography remains the initial test of choice, and careful assessment of the right system aids in the diagnosis and prognosis of the disease. Right heart catheterization remains the gold standard of diagnosis and key guidance of treatment. Multidisciplinary approach is recommended for the care of patients with PH. Treatment selection is based on individual risk stratification of patients, and early referral to specialized PH centers improves outcomes of patients. Treating PH is complex and is best carried out in PH centers and with multidisciplinary approach. Early diagnosis and referral to those centers are key not to delay treatment.

Keywords: hypertension, pulmonary; phosphodiesterase 5 inhibitors.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
ECHO probability score diagnostic algorithm
Figure 2
Figure 2
RHC, right heart catheterization; CCB, calcium channel blockers; NYHA, New York Heart Association; ERA, endothelin receptor antagonists; PDE5, phosphodiesterase type 5 inhibitor.
See this image and copyright information in PMC

References

    1. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53:1801913 10.1183/13993003.01913-2018 - DOI - PMC - PubMed
    1. Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint Task force for the diagnosis and treatment of pulmonary hypertension of the European Society of cardiology (ESC) and the European respiratory Society (ERS): endorsed by: association for European paediatric and congenital cardiology (AEPC), International Society for heart and lung transplantation (ISHLT). Eur Respir J 2015;46:903–75. 10.1183/13993003.01032-2015 - DOI - PubMed
    1. Kovacs G, Berghold A, Scheidl S, et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respi J 2009;34:888–94. 10.1183/09031936.00145608 - DOI - PubMed
    1. Bossone E, Paciocco G, Iarussi D, et al. The prognostic role of the ECG in primary pulmonary hypertension. Chest 2002;121:513–8. 10.1378/chest.121.2.513 - DOI - PubMed
    1. Olsson KM, Nickel NP, Tongers J, et al. Atrial flutter and fibrillation in patients with pulmonary hypertension. Int J Cardiol 2013;167:2300–5. 10.1016/j.ijcard.2012.06.024 - DOI - PubMed